Research Analyst Report on NanoViricides Rates Company “Outperform”; Separately, A “Fireside Chat” Interview of the Company’s President Dr. Anil Diwan Hosted by Mr ...

SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical ...

Ivermectin isn’t a cancer miracle drug, but influencers claim otherwise – here’s how to avoid sprinting past scientific evidence

Science works at a much slower pace than social media, opening a large window for early findings to be taken at face value ...

New Clinical Trials Offer Hope In The Fight Against Ebola In The Democratic Republic Of Congo

Multiple new clinical trials are underway to evaluate if various treatments will prove effective against the Bundibugyo Ebola ...

There's no treatment designed for the Ebola strain ravaging DRC. But now there's hope

The strain of the virus that's responsible for the current outbreak has no specific treatments or preventive measures. Three ...
The Lancet

Andes hantavirus: operationalising science in real time

Historically, outbreak research has been fragmented, delayed, and poorly integrated into emergency response. By the time protocols are developed, collaborations organised, funding secured, and ...

Wegovy, RSV vaccines among drugs on slow track in NZ

Rather than recognising authorisations provided by better-resourced overseas drug approval agencies, New Zealand requires ...

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

Detailed price information for Nanoviricides Inc (NNVC-A) from The Globe and Mail including charting and trades.
Nasdaq

Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides

SHELTON, CT / ACCESS Newswire / April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to ...